Literature DB >> 19093703

Antidepressants for the treatment of chronic pain.

Bénédicte Verdu1, Isabelle Decosterd, Thierry Buclin, Friedrich Stiefel, Alexandre Berney.   

Abstract

Chronic pain represents one of the most important public health problems and, in addition to classical analgesics, antidepressants are an essential part of the therapeutic strategy. This article reviews available evidence on the efficacy and safety of antidepressants in major chronic pain conditions; namely, neuropathic pain, headaches, low back pain, fibromyalgia, irritable bowel syndrome (IBS) and cancer pain. Studies, reviews and meta-analyses published from 1991 to March 2008 were retrieved through MEDLINE, PsycINFO and the Cochrane database using numerous key words for pain and antidepressants. In summary, evidence supports the use of tricyclic antidepressants in neuropathic pain, headaches, low back pain, fibromyalgia and IBS. The efficacy of the newer serotonin and norepinephrine reuptake inhibitors is less supported by evidence, but can be recommended in neuropathic pain, migraines and fibromyalgia. To date, evidence does not support an analgesic effect of serotonin reuptake inhibitors, but beneficial effects on well-being were reported in several chronic pain conditions. These results are discussed in the light of current insights in the neurobiology of pain, the reciprocal relationship between pain and depression, and future developments in this field of research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19093703     DOI: 10.2165/0003495-200868180-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  263 in total

1.  Selective serotonin reuptake inhibitors for migraine prophylaxis.

Authors:  S Landy; J McGinnis; D Curlin; S C Laizure
Journal:  Headache       Date:  1999-01       Impact factor: 5.887

2.  Maprotiline in chronic tension headache: a double-blind cross-over study.

Authors:  R Fogelholm; K Murros
Journal:  Headache       Date:  1985-07       Impact factor: 5.887

3.  Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.

Authors:  M B Max; S A Lynch; J Muir; S E Shoaf; B Smoller; R Dubner
Journal:  N Engl J Med       Date:  1992-05-07       Impact factor: 91.245

4.  The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study.

Authors:  A Yucel; S Ozyalcin; G Koknel Talu; E Kiziltan; B Yucel; O K Andersen; L Arendt-Nielsen; R Disci
Journal:  Eur J Pain       Date:  2004-11-13       Impact factor: 3.931

5.  Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy.

Authors:  F J Gómez-Pérez; R Choza; J M Ríos; A Reza; E Huerta; C A Aguilar; J A Rull
Journal:  Arch Med Res       Date:  1996       Impact factor: 2.235

6.  A comparison between placebo, pizotifen and 1-isopropyl-3-hydroxy-5-semicarbazono-6-oxo-2.3.5.6-tetrahydroindol (Divascan) in migraine prophylaxis.

Authors:  P O Osterman
Journal:  Acta Neurol Scand       Date:  1977-07       Impact factor: 3.209

7.  A trial of opipramol in the treatment of migraine.

Authors:  H Jacobs
Journal:  J Neurol Neurosurg Psychiatry       Date:  1972-08       Impact factor: 10.154

Review 8.  Guidelines for the use of antidepressants in painful rheumatic conditions.

Authors:  Serge Perrot; Emmanuel Maheu; Rose-Marie Javier; Alain Eschalier; Anne Coutaux; Manuela LeBars; Philippe Bertin; Bernard Bannwarth; Richard Trèves
Journal:  Eur J Pain       Date:  2005-04-18       Impact factor: 3.931

9.  A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team.

Authors:  K Kieburtz; D Simpson; C Yiannoutsos; M B Max; C D Hall; R J Ellis; C M Marra; R McKendall; E Singer; G J Dal Pan; D B Clifford; T Tucker; B Cohen
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

10.  Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats.

Authors:  J C Eisenach; G F Gebhart
Journal:  Anesthesiology       Date:  1995-11       Impact factor: 7.892

View more
  42 in total

Review 1.  Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.

Authors:  S Vink; P F Alewood
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Psychopharmacology in psycho-oncology.

Authors:  Rosangela Caruso; Luigi Grassi; Maria Giulia Nanni; Michelle Riba
Journal:  Curr Psychiatry Rep       Date:  2013-09       Impact factor: 5.285

3.  Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome.

Authors:  Uri Ladabaum; Annie Sharabidze; Theodore R Levin; Wei K Zhao; Elaine Chung; Peter Bacchetti; Chengshi Jin; Barbara Grimes; Craig J Pepin
Journal:  Clin Gastroenterol Hepatol       Date:  2009-09-16       Impact factor: 11.382

4.  [Orthopedic specialists in an interdisciplinary setting. Multimodal therapy for chronic back pain].

Authors:  L Weh; U Marnitz
Journal:  Orthopade       Date:  2009-10       Impact factor: 1.087

Review 5.  New treatments for chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Adam C Strauss; Jordan D Dimitrakov
Journal:  Nat Rev Urol       Date:  2010-02-09       Impact factor: 14.432

Review 6.  Pharmacological options for the management of refractory cancer pain-what is the evidence?

Authors:  B Afsharimani; K Kindl; P Good; J Hardy
Journal:  Support Care Cancer       Date:  2015-03-07       Impact factor: 3.603

Review 7.  Drugging the pain epigenome.

Authors:  Ellen Niederberger; Eduard Resch; Michael J Parnham; Gerd Geisslinger
Journal:  Nat Rev Neurol       Date:  2017-05-26       Impact factor: 42.937

Review 8.  Monotherapy or combination therapy for fibromyalgia treatment?

Authors:  Elena Pita Calandre; Fernando Rico-Villademoros; Carmen María Rodríguez-López
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

9.  A Comparative Study of Trigger Point Therapy with Local Anaesthetic (0.5 % Bupivacaine) Versus Combined Trigger Point Injection Therapy and Levosulpiride in the Management of Myofascial Pain Syndrome in the Orofacial Region.

Authors:  Pranav Gupta; Virendra Singh; Sujata Sethi; Arun Kumar
Journal:  J Maxillofac Oral Surg       Date:  2015-12-11

10.  Recent advances in the treatment of pain.

Authors:  Mellar P Davis
Journal:  F1000 Med Rep       Date:  2010-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.